Lexeo Therapeutics Inc. Common Stock

LXEO | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.11

+$0.03 (+0.74%)

Sep 22, 2026, 2:32 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.74%

(1D)

Rating

Updated: Sep 18, 2026

25.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $322.33M

1D Range

4.09 4.31

52W Range

3.99 10.99

Valuation (TTM)

PE -3.55

PB 1.36

EV/EBITDA -1.35

Valuation (NTM)

Forward PE N/A

Forward PEG -0.29

Price Target $21.13

Cash Flow

FCF Yield -27.7%

SBC Adj. FCF Yield -32.0%

SBC Impact -15.6%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -85.8%

Dil EPS 3Y | 5Y 33.2% | -1.6%

FCF 3Y | 5Y -15.3% | -19.9%

Returns

ROA -34.2%

ROE -41.9%

ROIC -39.3%

Financial Health

Net Cash

$211.7M

Current Ratio 13.89

Interest Coverage -689.25

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features se...

Sector Healthcare

Industry Biotechnology

Employees 63

IPO Date Nov 2, 2023

Website www.lexeotx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$20

Upside

+386.62%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞